

Monthly report

CARLSON INVESTMENTS SE

for the period from 01.04.2022 to 30.04.2022

Board of Directors of CARLSON INVESTMENTS SE with its registered seat in Warsaw (hereinafter referred to as the Issuer or the Company) hereby presents attached the monthly report for April 2022.

Legal Basis:

Legal basis: para. 16 of the Annex to Resolution No. 293/2010 of the WSE Management Board in Warsaw S.A. of 31.03.2010. "Good Practices of Companies Listed on the NewConnect."

Persons representing the Issuer

Aleksander Gruszczyński President of the Management Board

Warsaw, 13th May 2022

MedTech

Table of contents

- 1. Description of trends and events in the Issuer's environment,
- 2. List of reports published by the Issuer in April 2022,
- 3. Information on the achievement of issue objectives,
- 4. Investor Calendar.

1. DESCRIPTION OF TRENDS AND EVENTS IN THE ISSUER'S ENVIRONMENT

On April 13, 2022, the Issuer's merger previously acting as a joint stock company under Polish law under the business name CARLSON INVESTMENTS SPÓŁKA AKCYJNA, with its registered seat in Warsaw (00-125), Emilii Plater 49, Poland, entered into the Register of Entrepreneurs of the National Court Register under KRS no. 0000148769, Tax Identification Number 6342463031, Business Identification Number 277556406, with CARLSON TECH VENTURES Akciová společnost, with its registered seat in Český Těšín, address Hlavní třída 87/2, 737 01 Český Těšín, Czech Republic entered into the Commercial Register kept by the District Court in Ostrava, Section B under No. 11369, ID No. 11813385. As a result of the registration by the District Court for the Capital City of Warsaw in Warsaw of the merger, the Issuer assumed the legal form of a European Company and currently operates under the name of CARLSON INVESTMENTS SE with its registered office in Warsaw (00-125) at ul. Emilii Plater 49, Poland, entered in the Register of Entrepreneurs of the National Court Register under KRS 0000965148, NIP 6342463031, REGON 277556406. The Issuer explains that NIP and REGON numbers have not changed.

The merger took place on the terms set out in the Merger Plan of December 8, 2021 made available to the public, free of charge, on the websites of the merging companies, respectively, at CARLSON INVESTMENTS S.A. - https://carlsonvc.com/, CARLSON TECH VENTURES Akciová společnost - https://carlsontechvc.com/ as well as in the Issuer's current report ESPI no 37/2021 on 8 December 2021. The merger was effected through the acquisition of CARLSON TECH VENTURES Akciová společnost by CARLSON INVESTMENTS S.A., in accordance with the provisions of Article 2 (1) in connection with Article 17 (2) (a) and 18 of the Council Regulation (EC) No. 2157/2001 of 8 October 2001 on the Statute for a European company (SE) (Official Journal of the European Union L No. 294, p. 1). The merger was approved by the General Meeting of Shareholders of the Issuer on January 20, 2022 by Resolution No. 8.

Currently, the Company's share capital is expressed in EURO and amounts to: EUR 6,682,783.80 (in words: six million six hundred eighty-two thousand seven hundred eighty-three EURO 80/100) and is divided into 7,955,695 (seven million nine hundred fifty-five thousand six hundred ninety-five) shares with a nominal value of EUR 0.84 (eighty-four euro cents) each.

Along with the registration of the merger, amendments to the Company's Articles of Association resulting from the resolutions of the Extraordinary General Meeting of January 20, 2022 were registered. In connection with the adoption of the legal form of the European Company, there were no changes in the composition of the Issuer's bodies, there were no changes in the rights vested in the shareholders of the Company's shares, with the exception of a change in their nominal value (expression in EURO) and the Company continues its legal existence and activities in the form of a European Company.

On April 19, 2022, the Issuer's Management Board signed a loan agreement, under which it agreed to grant a loan to UAVLAS Limited Liability Company (UAVLAS, the Borrower), based in Warsaw, i.e. a company belonging to the investment portfolio of the partner entity CARLSON ASIEVIG ALFA. to support the development process in the amount of EUR 10 thousand with interest on market conditions.

UAVLAS is an innovative startup which is the author of the concept of the precise landing system for drones. The subject of the project is to create a system for precise landing on the so-called "last meters" working independently of the weather and geolocation conditions, consisting of a ground-based transmitter (landing platform) and a lightweight on-board receiver on a drone (Plug&Play) and software enabling the system to work with commonly known autopilots.

The parties agreed that the loan shall be repaid to the Issuer by 31.12.2022 or the loan shall be converted into new shares in increased share capital of UAVLAS, which shall be taken up by the Issuer or an entity from the capital group of the Issuer indicated by the Issuer. The Issuer is obliged to submit a declaration of readiness to take up the shares by 31-12-2022. The Issuer or an entity from the Issuer's Capital Group shall be entitled to subscribe for shares in each case not exceeding the value of EUR 1,000,000.00. The Board of the Issuer considers UAVLAS company as an entity with high development potential on the Polish and international market.

Subsidiary of the Issuer: Helvexia Pay Limited Liability Company. (hereinafter: "Helvexia Pay") was entered in the Register of Small Payment Institutions on 21 April 2022. According to the Register maintained by the Office of the Financial Supervision Authority, Helvexia Pay's entry is number MIP141/2022.

Consequently, in accordance with Article 117g(1) of the Payment Services Act, Helvexia Pay sp. z o.o. may perform payment services activities as a small payment institution

In April 2022, the Issuer realized the next steps related to the formalized cooperation with Carlson Ventures International Limited (CVI) and the partner entity CARLSON ASI EVIG ALFA in the coordination of investment activities. In the month under review, portfolio companies of the CARLSON ASI EVIG ALFA Fund, thanks to the provision of access to funding for innovative projects and the Fund's experience, continue successfully with their commenced projects...

mamy.link https://mamy.link/

Mamy.link - In April another project joined the CARLSON ASI EVIG ALFA portofolio . <u>Mamy.link</u> is a project whose aim is to create a system consisting of an IoT device and a SaaS platform allowing to extend the scope of services of gynecological surgeries in the area of prenatal tests. The solution will allow sharing ultrasound examination results, in the form of high quality 3D models, with parents and selected individuals (e.g. family members). After first experiments with processing of 3D images from ultrasound and attempts to distribute them, a solution in the form of SaaS platform was proposed, which would allow for browsing, viewing, rotating and sharing 3D models of babies in the womb in a simple way. It is worth noting that the concept of the product was quickly consulted with the medical community, which evaluated the idea very positively.

目 TERRABIO

www.terrabio.tech

TerraBio - a Wrocław-based startup developing a state-of-the-art, mobile genetic analyzer which, thanks to the use of a proprietary diagnostic system, makes it possible to conduct research in the area of agriculture and food safety by quickly identifying pathogens or genetic mutations. Thanks to the device, the user will receive a semi-quantitative result on the presence of pathogens in a sample in just 60-90 minutes. Currently, farmers have to wait up to 14 days for the result of a test performed using highly precise genetic methods. Terralyzer[®] can detect up to 16 pathogens from a single sample. It is worth noting that the solution effectively reduces the cost of testing. The Terrabio team predicts that the unit cost of testing 4 pathogens will not exceed 100 PLN. The innovation of the tests performed by the device is based on a patented heating, measuring and detection system in cooperation with the so-called "gold standard" in pathogen diagnostics, i.e. real-time PCR. One of the significant advantages of this solution is that there is no

requirement to maintain a constant, low temperature of test kit storage, which makes the test possible to perform in almost any conditions. An additional advantage of this solution is the process of taking a sample and performing the test. The process is simple and can be handled by any user. In 2021, the company successfully conducted field tests on Top Farms Poland fields within the Top Farms Technology Zone and on crops in Spain and Portugal. The company's solution is characterized by over 99 percent efficiency in detecting all pathogens that have DNA. Terrabio is also a response to the increasing restrictions on the use of pesticides and to ensure the quality of food produced within the European Union. Terralyzer® and its dedicated test panels will enable the reduction of pesticide treatments in food production, thus contributing to food quality. In April Terrabio received patent protection for Terralyzer® in the Polish market. With this protection, Terrabio will be able to significantly accelerate the commercialization process of the product. Terrabio is also in the process of filing patents for Terralyzer® in the USA and EU.

1. SUMMARY OF REPORTS PUBLISHED BY THE ISSUER IN FEBRUARY 2022,

During the month covered by this report, the Company published the following reports in the <u>EBI system:</u>

13-04-2022 | Current Report No. 8/2022 - Merger of the Issuer - CARLSON INVESTMENT S.A. (Acquiring Company) with CARLSON TECH VENTURES Akciová společnost (Acquired Company), adoption by the Issuer of the legal form of the European SE Company and amendment to the Company's Articles of Association.

14-04-2022 | Current Report No. 9/2022 - monthly report for March 2022.

During the month covered by this report, the Company published the following reports in the ESPI system:

13-03-2022 | Current report no 8/2022 - Merger of the Issuer - CARLSON INVESTMENT S.A. (Acquiring Company) with CARLSON TECH VENTURES Akciová společnost (Acquired Company), adoption by the Issuer of the legal form of the European SE Company and amendment to the Company's Articles of Association.

20-04-2022 | Current Report No. 9/2022 - confidential information: Information about the conclusion of a loan agreement.

22-04-2022 | Current report no 10/2022 - confidential information: Entry of Helvexia Pay sp. z o. o. to the Register of small payment institutions

2. INFORMATION ON THE ACHIEVEMENT OF ISSUE OBJECTIVES,

As of April 2022, there were no plans to use the proceeds from the share issuance.

3. INVESTOR CALENDAR,

By June 14, 2022, the Board of Directors of the Issuer will make public the contents of the monthly report for May 2022.

On May 16, 2022, the Board of Directors of the Issuer will make public the contents of the Interim Report for Q1 2022.

On May 31, 2022, the Issuer will publish its 2021 Annual Report.





4.637

4.637

4.637